{"pmid":32456695,"pmcid":"PMC7249977","title":"Clinical analysis of sinus bradycardia in patients with severe COVID-19 pneumonia.","text":["Clinical analysis of sinus bradycardia in patients with severe COVID-19 pneumonia.","Crit Care","Hu, Lijuan","Gong, Linjing","Jiang, Zhilong","Wang, Qibing","Zou, Yunzeng","Zhu, Lei","32456695"],"journal":"Crit Care","authors":["Hu, Lijuan","Gong, Linjing","Jiang, Zhilong","Wang, Qibing","Zou, Yunzeng","Zhu, Lei"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32456695","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1186/s13054-020-02933-3","keywords":["ace2","covid-19","clinical manifestation","severe pneumonia","sinus bradycardia"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668141322626662400,"score":9.490897,"similar":[{"pmid":32306657,"title":"[Clinical features and outcome of treatment for novel coronavirus pneumonia: a meta-analysis].","text":["[Clinical features and outcome of treatment for novel coronavirus pneumonia: a meta-analysis].","Objective: To investigate the clinical features and outcome of treatment for novel coronavirus pneumonia. Methods: Literature on novel coronavirus pneumonia was retrieved from PubMed and EMBASE databases. The relevant data was extracted and a meta-analysis was performed using StatsDirect statistical software V.2.8.0 to calculate the combined odds ratio. Results: Seven studies were included, consisting of 1594 cases. The meta-analysis result showed that the most common clinical symptoms of the novel coronavirus pneumonia were fever (91.6%) and cough (64.5%), followed by dyspnea (32.8%) and sputum (28.1%). Headache (10.5%), sore throat (11.2%), hemoptysis (3.2%), diarrhea (6.6%) and the other symptoms were relatively rare. Aspartate aminotransferase (29%), alanine transaminase (22.7%), and total bilirubin (11.7%) levels were elevated, except for serum albumin levels (80.4%). The common therapeutic agents used were antibiotics (87.7%), antiviral drugs (75.5%), and glucocorticoids (26.6%), while antifungal agents (7.7%) were used in few. Mechanical ventilation (13.4%), extracorporeal membrane oxygenation (1.9%), and continuous renal replacement therapy (3.8%) were used in severe cases. The rate of mortality in hospital was 7.7%, respectively. Heterogeneity between studies was significant; however, subgroup and sensitivity analysis had failed to identify clear sources of heterogeneity. Conclusion: Fever, cough and liver dysfunction are the main clinical manifestations of this disease and the mortality rate is low.","Zhonghua Gan Zang Bing Za Zhi","Wu, Y Y","Li, H Y","Xu, X B","Zheng, K X","Qi, X S","Guo, X Z","32306657"],"abstract":["Objective: To investigate the clinical features and outcome of treatment for novel coronavirus pneumonia. Methods: Literature on novel coronavirus pneumonia was retrieved from PubMed and EMBASE databases. The relevant data was extracted and a meta-analysis was performed using StatsDirect statistical software V.2.8.0 to calculate the combined odds ratio. Results: Seven studies were included, consisting of 1594 cases. The meta-analysis result showed that the most common clinical symptoms of the novel coronavirus pneumonia were fever (91.6%) and cough (64.5%), followed by dyspnea (32.8%) and sputum (28.1%). Headache (10.5%), sore throat (11.2%), hemoptysis (3.2%), diarrhea (6.6%) and the other symptoms were relatively rare. Aspartate aminotransferase (29%), alanine transaminase (22.7%), and total bilirubin (11.7%) levels were elevated, except for serum albumin levels (80.4%). The common therapeutic agents used were antibiotics (87.7%), antiviral drugs (75.5%), and glucocorticoids (26.6%), while antifungal agents (7.7%) were used in few. Mechanical ventilation (13.4%), extracorporeal membrane oxygenation (1.9%), and continuous renal replacement therapy (3.8%) were used in severe cases. The rate of mortality in hospital was 7.7%, respectively. Heterogeneity between studies was significant; however, subgroup and sensitivity analysis had failed to identify clear sources of heterogeneity. Conclusion: Fever, cough and liver dysfunction are the main clinical manifestations of this disease and the mortality rate is low."],"journal":"Zhonghua Gan Zang Bing Za Zhi","authors":["Wu, Y Y","Li, H Y","Xu, X B","Zheng, K X","Qi, X S","Guo, X Z"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32306657","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.3760/cma.j.cn501113-20200224-00067","keywords":["2019 novel coronavirus pneumonia","antiviral","clinical manifestation","mortality","treatment"],"e_drugs":["Bilirubin"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138491230093314,"score":82.24694},{"pmid":32470153,"title":"Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19.","text":["Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19.","OBJECTIVE: To investigate the inflammatory factors and lymphocyte subsets which play an important role in the course of severe COVID-19. METHODS: A total of 27 patients with severe COVID-19 who were admitted to Tongji Hospital in Wuhan from 1 to 21 February 2020 were recruited to the study. The characteristics of interleukin (IL)-1beta, IL-2 receptor (IL-2R), IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-alpha, C-reactive protein (CRP), serum ferritin and procalcitonin (PCT), and lymphocyte subsets of these patients were retrospectively compared before and after treatment. RESULTS: Before treatment, there was no significant difference in most inflammatory factors (IL-1beta, IL-2R, IL-6, IL-8, IL-10, CRP and serum ferritin) between male and female patients. Levels of IL-2R, IL-6, TNF-alpha and CRP decreased significantly after treatment, followed by IL-8, IL-10 and PCT. Serum Ferritin was increased in all patients before treatment, but did not decrease significantly after treatment. IL-1beta was normal in most patients before treatment. Lymphopenia was common among these patients with severe COVID-19. Analysis of lymphocyte subsets showed that CD4(+) and particularly CD8(+) T lymphocytes increased significantly after treatment. However, B lymphocytes and natural killer cells showed no significant changes after treatment. CONCLUSIONS: A pro-inflammatory response and decreased level of T lymphocytes were associated with severe COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Ni, Ming","Tian, Fang-Bing","Xiang, Dan-Dan","Yu, Bing","32470153"],"abstract":["OBJECTIVE: To investigate the inflammatory factors and lymphocyte subsets which play an important role in the course of severe COVID-19. METHODS: A total of 27 patients with severe COVID-19 who were admitted to Tongji Hospital in Wuhan from 1 to 21 February 2020 were recruited to the study. The characteristics of interleukin (IL)-1beta, IL-2 receptor (IL-2R), IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-alpha, C-reactive protein (CRP), serum ferritin and procalcitonin (PCT), and lymphocyte subsets of these patients were retrospectively compared before and after treatment. RESULTS: Before treatment, there was no significant difference in most inflammatory factors (IL-1beta, IL-2R, IL-6, IL-8, IL-10, CRP and serum ferritin) between male and female patients. Levels of IL-2R, IL-6, TNF-alpha and CRP decreased significantly after treatment, followed by IL-8, IL-10 and PCT. Serum Ferritin was increased in all patients before treatment, but did not decrease significantly after treatment. IL-1beta was normal in most patients before treatment. Lymphopenia was common among these patients with severe COVID-19. Analysis of lymphocyte subsets showed that CD4(+) and particularly CD8(+) T lymphocytes increased significantly after treatment. However, B lymphocytes and natural killer cells showed no significant changes after treatment. CONCLUSIONS: A pro-inflammatory response and decreased level of T lymphocytes were associated with severe COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Ni, Ming","Tian, Fang-Bing","Xiang, Dan-Dan","Yu, Bing"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470153","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26070","keywords":["covid-19","lymphopenia","pro-inflammatory","severe pneumonia"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668167110047563776,"score":68.664024},{"pmid":32338347,"pmcid":"PMC7183927","title":"COVID-19 in Children: Clinical Approach and Management.","text":["COVID-19 in Children: Clinical Approach and Management.","COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major public health crisis threatening humanity at this point in time. Transmission of the infection occurs by inhalation of infected droplets or direct contact with soiled surfaces and fomites. It should be suspected in all symptomatic children who have undertaken international travel in the last 14 d, all hospitalized children with severe acute respiratory illness, and asymptomatic direct and high-risk contacts of a confirmed case. Clinical symptoms are similar to any acute respiratory viral infection with less pronounced nasal symptoms. Disease seems to be milder in children, but situation appears to be changing. Infants and young children had relatively more severe illness than older children. The case fatality rate is low in children. Diagnosis can be confirmed by Reverse transcriptase - Polymerase chain reaction (RT-PCR) on respiratory specimen (commonly nasopharyngeal and oropharyngeal swab). Rapid progress is being made to develop rapid diagnostic tests, which will help ramp up the capacity to test and also reduce the time to getting test results. Management is mainly supportive care. In severe pneumonia and critically ill children, trial of hydroxychloroquine or lopinavir/ritonavir should be considered. As per current policy, children with mild disease also need to be hospitalized; if this is not feasible, these children may be managed on ambulatory basis with strict home isolation. Pneumonia, severe disease and critical illness require admission and aggressive management for acute lung injury and shock and/or multiorgan dysfunction, if present. An early intubation is preferred over non-invasive ventilation or heated, humidified, high flow nasal cannula oxygen, as these may generate aerosols increasing the risk of infection in health care personnel. To prevent post discharge dissemination of infection, home isolation for 1-2 wk may be advised. As of now, no vaccine or specific chemotherapeutic agents are approved for children.","Indian J Pediatr","Sankar, Jhuma","Dhochak, Nitin","Kabra, S K","Lodha, Rakesh","32338347"],"abstract":["COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major public health crisis threatening humanity at this point in time. Transmission of the infection occurs by inhalation of infected droplets or direct contact with soiled surfaces and fomites. It should be suspected in all symptomatic children who have undertaken international travel in the last 14 d, all hospitalized children with severe acute respiratory illness, and asymptomatic direct and high-risk contacts of a confirmed case. Clinical symptoms are similar to any acute respiratory viral infection with less pronounced nasal symptoms. Disease seems to be milder in children, but situation appears to be changing. Infants and young children had relatively more severe illness than older children. The case fatality rate is low in children. Diagnosis can be confirmed by Reverse transcriptase - Polymerase chain reaction (RT-PCR) on respiratory specimen (commonly nasopharyngeal and oropharyngeal swab). Rapid progress is being made to develop rapid diagnostic tests, which will help ramp up the capacity to test and also reduce the time to getting test results. Management is mainly supportive care. In severe pneumonia and critically ill children, trial of hydroxychloroquine or lopinavir/ritonavir should be considered. As per current policy, children with mild disease also need to be hospitalized; if this is not feasible, these children may be managed on ambulatory basis with strict home isolation. Pneumonia, severe disease and critical illness require admission and aggressive management for acute lung injury and shock and/or multiorgan dysfunction, if present. An early intubation is preferred over non-invasive ventilation or heated, humidified, high flow nasal cannula oxygen, as these may generate aerosols increasing the risk of infection in health care personnel. To prevent post discharge dissemination of infection, home isolation for 1-2 wk may be advised. As of now, no vaccine or specific chemotherapeutic agents are approved for children."],"journal":"Indian J Pediatr","authors":["Sankar, Jhuma","Dhochak, Nitin","Kabra, S K","Lodha, Rakesh"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32338347","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1007/s12098-020-03292-1","keywords":["ards","acute lung injury","acute respiratory distress syndrome","covid-19","hydroxychloroquine","lopinavir","multiorgan dysfunction","ritonavir","sars-cov-2","severe pneumonia"],"e_drugs":["Hydroxychloroquine","lopinavir-ritonavir drug combination"],"topics":["Prevention","Diagnosis","Transmission","Treatment"],"weight":1,"_version_":1666138494216437760,"score":65.87759},{"pmid":32246317,"pmcid":"PMC7124128","title":"Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2.","text":["Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2.","Severe coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy, the difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 has not been analyzed. Coagulation results and clinical features of consecutive patients with severe pneumonia induced by SARS-CoV2 (COVID group) and non-SARS-CoV2 (non-COVID group) in Tongji hospital were retrospectively analyzed and compared. Whether patients with elevated D-dimer could benefit from anticoagulant treatment was evaluated. There were 449 COVID patients and 104 non-COVID patients enrolled into the study. The 28-day mortality in COVID group was approximately twofold of mortality in non-COVID group (29.8% vs. 15.4%, P = 0.003), COVID group were older (65.1 +/- 12.0 vs. 58.4 +/- 18.0, years, P < 0.001) and with higher platelet count (215 +/- 100 vs. 188 +/- 98, x10(9)/L, P = 0.015), comparing to non-COVID group. The 28-day mortality of heparin users were lower than nonusers In COVID group with D-dimer > 3.0 mug/mL (32.8% vs. 52.4%, P = 0.017). Patients with severe pneumonia induced by SARS-CoV2 had higher platelet count than those induced by non-SARS-CoV2, and only the former with markedly elevated D-dimer may benefit from anticoagulant treatment.","J Thromb Thrombolysis","Yin, Shiyu","Huang, Ming","Li, Dengju","Tang, Ning","32246317"],"abstract":["Severe coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy, the difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 has not been analyzed. Coagulation results and clinical features of consecutive patients with severe pneumonia induced by SARS-CoV2 (COVID group) and non-SARS-CoV2 (non-COVID group) in Tongji hospital were retrospectively analyzed and compared. Whether patients with elevated D-dimer could benefit from anticoagulant treatment was evaluated. There were 449 COVID patients and 104 non-COVID patients enrolled into the study. The 28-day mortality in COVID group was approximately twofold of mortality in non-COVID group (29.8% vs. 15.4%, P = 0.003), COVID group were older (65.1 +/- 12.0 vs. 58.4 +/- 18.0, years, P < 0.001) and with higher platelet count (215 +/- 100 vs. 188 +/- 98, x10(9)/L, P = 0.015), comparing to non-COVID group. The 28-day mortality of heparin users were lower than nonusers In COVID group with D-dimer > 3.0 mug/mL (32.8% vs. 52.4%, P = 0.017). Patients with severe pneumonia induced by SARS-CoV2 had higher platelet count than those induced by non-SARS-CoV2, and only the former with markedly elevated D-dimer may benefit from anticoagulant treatment."],"journal":"J Thromb Thrombolysis","authors":["Yin, Shiyu","Huang, Ming","Li, Dengju","Tang, Ning"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32246317","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1007/s11239-020-02105-8","keywords":["coagulopathy","coronavirus disease 2019","d-dimer","severe pneumonia"],"locations":["Tongji"],"e_drugs":["Heparin"],"topics":["Diagnosis"],"weight":1,"_version_":1666138492053225474,"score":64.649025},{"pmid":32314274,"title":"Clinical Manifestation and Laboratory Characteristics of SARS-CoV-2 Infection in Pregnant Women.","text":["Clinical Manifestation and Laboratory Characteristics of SARS-CoV-2 Infection in Pregnant Women.","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic has become a major challenge to public health in China and other countries, considering its pathogenicity across all age groups. Pregnancy is a unique physiological condition, and is characterized by altered immunity and elevated hormone levels to actively tolerate the semi-allogeneic fetus, which undergoes a sudden and substantial fluctuation during the immediate postpartum period. Changes in clinical features, laboratory characteristics, and imaging features of pregnant women during the pre-partum and post-partum periods require further elucidation. Here, we retrospectively analyzed the clinical features, laboratory characteristics, and imaging features of eight pregnant cases of SARS-CoV-2 infection during the pre-partum and post-partum periods. Our results showed that four of the eight pregnant women were asymptomatic before delivery but became symptomatic post-partum. Correspondingly, white blood cell (WBC) counts increased and lymphocyte (LYMPH) counts decreased. C-reactive protein (CRP) levels in the serum also increased to a higher level than those in general pregnancy. Therefore, it is imperative to closely monitor laboratory parameters including the WBC count, LYMPH count, and CRP, along with other imaging features in chest CT scans, to promptly prevent, diagnose, and treat a SARS-CoV-2 infection during pregnancy.","Virol Sin","Wu, Chunchen","Yang, Wenzhong","Wu, Xiaoxue","Zhang, Tianzhu","Zhao, Yaoyao","Ren, Wei","Xia, Jianbo","32314274"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic has become a major challenge to public health in China and other countries, considering its pathogenicity across all age groups. Pregnancy is a unique physiological condition, and is characterized by altered immunity and elevated hormone levels to actively tolerate the semi-allogeneic fetus, which undergoes a sudden and substantial fluctuation during the immediate postpartum period. Changes in clinical features, laboratory characteristics, and imaging features of pregnant women during the pre-partum and post-partum periods require further elucidation. Here, we retrospectively analyzed the clinical features, laboratory characteristics, and imaging features of eight pregnant cases of SARS-CoV-2 infection during the pre-partum and post-partum periods. Our results showed that four of the eight pregnant women were asymptomatic before delivery but became symptomatic post-partum. Correspondingly, white blood cell (WBC) counts increased and lymphocyte (LYMPH) counts decreased. C-reactive protein (CRP) levels in the serum also increased to a higher level than those in general pregnancy. Therefore, it is imperative to closely monitor laboratory parameters including the WBC count, LYMPH count, and CRP, along with other imaging features in chest CT scans, to promptly prevent, diagnose, and treat a SARS-CoV-2 infection during pregnancy."],"journal":"Virol Sin","authors":["Wu, Chunchen","Yang, Wenzhong","Wu, Xiaoxue","Zhang, Tianzhu","Zhao, Yaoyao","Ren, Wei","Xia, Jianbo"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314274","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s12250-020-00227-0","keywords":["clinical manifestation","immunity","laboratory characteristics","pregnant women","sars-cov-2"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493529620481,"score":61.691303}]}